SS
NBIX icon

SBI Securities’s Neurocrine Biosciences NBIX Stock Holding History

SBI Securities’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12K Buy
71
+10
+16% +$1.48K ﹤0.01% 1747
2026
Q1 		$8.04K Buy
61
+9
+17% +$1.19K ﹤0.01% 1828
2025
Q4 		$7.38K Sell
52
-9
-15% -$1.3K ﹤0.01% 1862
2025
Q3 		$8.56K Buy
61
+15
+33% +$2.03K ﹤0.01% 1834
2025
Q2 		$5.78K Buy
46
+19
+70% +$2.18K ﹤0.01% 1920
2025
Q1 		$2.99K Sell
27
-22
-45% -$2.79K ﹤0.01% 2122
2024
Q4 		$6.69K Buy
+49
New +$6.06K ﹤0.01% 1808

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SBI Securities's NBIX Position: Q2 2026 in Review

SBI Securities increased its Neurocrine Biosciences (NBIX) stake by 16% in Q2 2026, buying an estimated $1.48K and bringing the position to 71 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #1747.

SBI Securities first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • SBI Securities held 71 shares of Neurocrine Biosciences worth $12K as of Q2 2026.
  • SBI Securities bought 10 Neurocrine Biosciences shares in Q2 2026, an estimated $1.48K.
  • Neurocrine Biosciences made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1747 holding.
  • SBI Securities first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.